EMBC vs MDT
EMBC: A dedicated diabetes care company specializing in insulin delivery systems and pen needles for millions of users worldwide. MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries.
Side-by-side fundamentals
| Metric | EMBC | MDT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.25 | $81.89 | |
| Market cap as of 2026-07-23 | $193M | $105.1B | |
| P/E as of 2026-07-23 | 1.72 | 21.88 | EMBC lower |
| PEG as of 2026-07-23 | -0.17 | 2.90 | EMBC lower |
| Net margin as of 2026-07-23 | +10.7% | +13.2% | MDT higher |
| Gross margin as of 2026-07-23 | +61.9% | +65.3% | MDT higher |
| Operating margin as of 2026-07-23 | +25.8% | +17.8% | EMBC higher |
| ROE as of 2026-07-23 | +6.1% | +9.8% | MDT higher |
| ROA as of 2026-07-23 | +10.3% | +5.2% | EMBC higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.57 | EMBC lower |
| Revenue growth (YoY) as of 2026-07-23 | -3.4% | +8.4% | MDT higher |
| Revenue CAGR (3y) SEC XBRL | -1.5% | +5.2% | MDT higher |
| Dividend yield as of 2026-07-23 | +1.2% | +3.5% | MDT higher |
| Dividend streak (yrs) SEC XBRL | 4 | 5 | MDT higher |
| Beta as of 2026-07-23 | 0.84 | 0.57 | |
| 1-year return as of 2026-07-22 close | -67.2% | -10.6% | MDT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.